预约演示
更新于：2025-05-16
Dalfopristin/Quinupristin
奎奴普丁/达福普汀
更新于：2025-05-16
概要
基本信息
药物类型 小分子化药 |
别名 Quinupristin/Dalfopristin、RP 57669/RP54476、RP 59500 + [4] |
作用方式 抑制剂 |
作用机制 50S subunit抑制剂(50S核糖体亚基抑制剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 英国 (1999-07-01), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C87H117N13O19S2 |
InChIKeyPPKJUHVNTMYXOD-PZGPJMECSA-N |
CAS号126602-89-9 |
Sequence Code 524728955
关联
1
项与 奎奴普丁/达福普汀 相关的临床试验NCT00240747
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
100 项与 奎奴普丁/达福普汀 相关的临床结果
登录后查看更多信息
100 项与 奎奴普丁/达福普汀 相关的转化医学
登录后查看更多信息
100 项与 奎奴普丁/达福普汀 相关的专利（医药）
登录后查看更多信息
1,955
项与 奎奴普丁/达福普汀 相关的文献（医药）2025-04-01JOURNAL OF WATER AND HEALTH
A comprehensive One Health investigation of erythromycin and quinupristin/dalfopristin resistant Enterococcus spp. in Iran
Article
作者: Kheljan, Malek Namaki ; Hasanpour, Fereshteh ; Iranpour, Sohrab ; Ghalehbin, Behnam Mohammadi ; Khademi, Farzad ; Arzanlou, Mohsen ; Jannati, Elham
ABSTRACT:
Enterococci, flagged by the WHO as a rising cause of antibiotic-resistant infections, make surveillance crucial to control resistant strains. We investigated the resistance to linezolid, quinupristin/dalfopristin (Q/D), and erythromycin in Enterococcus faecalis (n = 251) and Enterococcus faecium (n = 434) isolates collected from patients, healthy carriers, hospitals, poultry, livestock, and municipal wastewater in Ardabil, Iran. The isolates were tested for resistance using phenotypic and genotypic methods. Although none of the isolates were resistant to linezolid, 24.9% of E. faecium isolates were resistant to Q/D, particularly those from patients and poultry slaughterhouse wastewater effluent (P < 0.05). The Q/D resistance genes msrC and ermB were detected in 76.85 and 20.37% of E. faecium isolates, respectively. Erythromycin resistance was common in E. faecalis (51.8%) and E. faecium (37.5%), with no significant difference between sources. However, isolates from patients and livestock wastewater had higher erythromycin MICs. Erythromycin resistance genes, such as ermB, ermC, ermTR, and ermA, were found in 80.7, 41.2, 26.5, and 19% of E. faecium and 80.3, 51.6, 22.4, and 25.8% of E. faecalis isolates, respectively. In conclusion, linezolid is a viable treatment for enterococcal infections in Ardabil, but widespread erythromycin- and Q/D-resistant enterococci pose a public health risk.
2025-02-01Zhongguo shi yan xue ye xue za zhi
[Clinical and Laboratory Characteristics of Streptococcus mitis Causing Bloodstream Infection in Children with Hematological Disease].
Article
作者: Chen, Xiao-Juan ; Zhu, Guo-Qing ; Lin, Qing-Song ; Tian, Zhi-Ying ; Guo, Ye ; Lyu, Yan-Xia ; Yang, Wen-Yu ; Wang, Zhao ; Fan, Yu-Long
OBJECTIVE:
To investigate the risk factors, clinical characteristics, and bacterial resistance of bloodstream infections caused by Streptococcus mitis in children with hematological disease, so as to provide a reference for infection control.
METHODS:
The clinical information and laboratory findings of pediatric patients complicated with blood cultures positive for Streptococcus mitis from January 2018 to December 2020 in the Institute of Hematology & Blood Diseases Hospital were searched and collected. The clinical characteristics, susceptibility factors, and antibiotic resistance of the children were retrospectively analyzed.
RESULTS:
Data analysis from 2018 to 2020 showed that the proportion of Streptococcus mitis isolated from bloodstream infections in children (≤14 years old) with hematological diseases was the highest (19.91%) and significantly higher than other bacteria, accounting for 38.64% of Gram-positive cocci, and presented as an increasing trend year by year. A total of 427 children tested positive blood cultures, including 85 children with bloodstream infections caused by Streptococcus mitis who tested after fever. Most children experienced a recurrent high fever in the early and middle stages (≤6 d) of neutropenia and persistent fever for more than 3 days. After adjusting the antibiotics according to the preliminary drug susceptibility results, the body temperature of most children (63.5%) returned to normal within 4 days. The 85 children were mainly diagnosed with acute myeloid leukemia (AML), accounting for 84.7%. The proportion of children in the neutropenia stage was 97.7%. The incidence of oral mucosal damage, lung infection, and gastrointestinal injury symptoms was 40%, 31.8%, and 27.1%, respectively. The ratio of elevated C-reactive protein (CRP) and procalcitonin was 65.9% and 9.4%, respectively. All isolated strains of Streptococcus mitis were not resistant to vancomycin and linezolid, and the resistance rate to penicillin, cefotaxime, levofloxacin, and quinupristin-dalfopristin was 10.6%, 8.2%, 9.4%, and 14.1%, respectively. None of children died due to bloodstream infection caused by Streptococcus mitis.
CONCLUSION:
The infection rate of Streptococcus mitis is increasing year by year in children with hematological diseases, especially in children with AML. Among them, neutropenia and oral mucosal damage after chemotherapy are high-risk infection factors. The common clinical symptoms include persistent high fever, oral mucosal damage, and elevated CRP. Penicillin and cephalosporins have good sensitivity. Linezolid, as a highly sensitive antibiotic, can effectively control infection and shorten the course of disease.
2024-12-01INFECTION
Changes in the epidemiology and antimicrobial resistance patterns of Streptococcus pneumoniae from pediatric community acquired pneumonia patients attended in a Chinese hospital during the COVID-19 pandemic
Article
作者: Ai, Ling ; Gong, Fang ; Zhou, Chanjuan ; Liu, Beizhong ; Fang, Liang
PURPOSE:
The COVID-19 pandemic has altered the infection dynamics of numerous pathogens. This study aimed to elucidate its impact on Streptococcus pneumoniae (S. pneumoniae) infections in children with community acquired pneumonia (CAP).
METHODS:
A retrospective analysis was conducted in pediatric CAP patients admitted before (2018-2019) and during (2020-2022) the COVID-19 pandemic. The epidemiology and antimicrobial resistance (AMR) patterns of S. pneumoniae were compared to reveal the impact of the pandemic.
RESULTS:
A total of 968 S. pneumoniae-associated pediatric CAP patients were enrolled. Although the positivity rate and gender of patients were stable across both periods, the age notably increased in 2021 and 2022. Additionally, significant changes were observed in the co-infections with several pathogens and the resistance rates to certain antibiotics during the COVID-19 pandemic. The resistance rate to clindamycin and quinupristin-dalfopristin increased, whereas the resistance rate to tetracycline, trimethoprim-sulfamethoxazole, telithromycin, and proportion of multi-drug resistant isolates decreased. The number of S. pneumoniae strains and resistant isolates exhibited similar seasonal patterns in 2018 and 2019, peaking in November or December with another minor peak in March or April. During the COVID-19 pandemic, there was a sharp decrease in February 2020 and no resurgence was observed at the end of 2022. Additionally, the minor peak was absent in 2020 and shifted to other months in 2021 and 2022.
CONCLUSIONS:
The COVID-19 pandemic has markedly altered the infection spectrum of S. pneumoniae in pediatric CAP patients, as evidenced by shifts in the age of patients, respiratory co-infections, AMR patterns, and seasonal trends.
1
项与 奎奴普丁/达福普汀 相关的新闻（医药）2024-07-14
上市批准生物类似药
100 项与 奎奴普丁/达福普汀 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 菌血症 | 美国 | 1999-09-21 | |
| 复杂皮肤和皮肤结构感染 | 美国 | 1999-09-21 | |
| 耐万古霉素肠球菌感染 | 美国 | 1999-09-21 | |
| 革兰氏阳性细菌感染 | 英国 | 1999-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用